SCHEMBL802288

SCHEMBL802288

CC(C)Nc1cc(C(C)C)nc2c1CCC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 5/20 0.43
NPSR1 Q6W5P4 2/20 0.37
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TSHR P16473 1/20 0.34
ACHE P22303 4/20 0.32
MAPK1 P28482 1/20 0.32
BPTF Q12830 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
BCHE P06276 3/20 0.32
GRIN1 Q05586 3/20 0.32
GRIN2A Q12879 3/20 0.32
CACNA2D1 P54289 3/20 0.31
CYP1A2 P05177 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801640 0.97 EHMT2 (0.40) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL802005 0.95 EHMT2 (0.39) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL13963025 0.83 NOS3 (0.39) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL10266627 0.82 NOS3 (0.38) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL10268953 0.81 EHMT2 (0.43) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL805577 0.78 NOS3 (0.43) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL12653919 0.77 NOS3 (0.42) EHMT2NPSR1KDM4EMAPTNOS3
SCHEMBL30162572 0.76 NOS3 (0.44) KDM4ENOS3NOS1NOS2MEN1
SCHEMBL22020688 0.76 NOS3 (0.44) KDM4ENOS3NOS1NOS2MEN1
SCHEMBL25803055 0.72 CYP2D6 (0.38) EHMT2NPSR1KDM4ENOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633210-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-01-21 US disclosed
US-8524720-B2 Substituted N-(pyrazol-5-yl)-pyrrolo[3,2-D]pyrimidin-4-amine useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-7951820-B2 Triazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-05-31 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed
US-7691853-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-06 US disclosed
US-7473691-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-01-06 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A EHMT2 2312/4885NPSR1 3425/4885KDM4E 1621/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 EHMT2 2550/4885NPSR1 3479/4885KDM4E 1040/4885
US-20070270444-A1 Pyrazole compounds useful as protein kinase inhibitors GSK3B, CDK3, GSK3A EHMT2 2312/4885NPSR1 3425/4885KDM4E 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.